

The Clinical Pharmacokinetics of Cladribine

Jan Liliemark

Department of Oncology, Karolinska Hospital, Stockholm, Sweden

Contents

Summary	120
1. Bioanalysis	121
2. Bioavailability	122
2.1 Oral Administration	122
2.2 Subcutaneous Administration	123
2.3 Rectal Administration	123
3. Distribution	123
3.1 Penetration of the Blood-Brain Barrier	123
4. Metabolism	124
4.1 Catabolism	124
4.2 Bioactivation	124
4.3 Intracellular Pharmacokinetics	124
4.4 Plasma/Cell Concentration Relationship	125
5. Pharmacodynamic Relationships	125
6. Excretion	127
7. Interaction	127
8. Interspecies Differences	128
9. Conclusion	129

Summary

Cladribine is a new purine nucleoside analogue with promising activity in low-grade lymphoproliferative disorders, childhood acute myelogenous leukaemia and multiple sclerosis. Reversed phase high performance liquid chromatography and radioimmunoassay have been used for the analysis of the plasma pharmacokinetics of cladribine. The major (inactive) metabolite in plasma, chloro-adenine, can only be detected by liquid chromatography.

The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%. The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m². The concentration in the cerebrospinal fluid is 25% of that in plasma in patients without central nervous system disease; in patients with meningeal disease, the cladribine concentration in the cerebrospinal fluid exceeds that in plasma.

Cladribine is a prodrug and needs intracellular phosphorylation to active nucleotides. The intracellular concentration of these metabolites is several hundred-fold higher than that of cladribine in plasma and they are retained in leukaemia cells with half-lives between 9 and >30 hours depending on diagnosis and

sampling schedule. There is no correlation between the plasma concentration of cladribine and that of the intracellular metabolites.

The renal clearance of cladribine is 51% of total clearance and 21 to 35% of an intravenously administered dose is excreted unchanged in the urine. Pretreatment with cladribine increases the intracellular accumulation of the active metabolite of cytarabine, cytosine arabinoside 5'-triphosphate, by 36 to 40%.

The first report on the synthesis and antileukemic effect of cladribine (2-chloro-2'-deoxycytidine, CdA) was published in 1972.^[1] Later it was discovered that severe immunodeficiency in children was, in a fraction of patients, caused by deficient adenosine deaminase (ADA).^[2] Deoxyadenosine accumulates in plasma and dATP in cells with high deoxycytidine kinase (dCK) activity. Such perturbations of the deoxyribonucleotide pools leads to DNA-strand breaks, poly(ADP)ribosyl transferase activation, consumption of NAD, ATP depletion and loss of viability.^[3] Cladribine and other C-2 halogenated purines (e.g. fludarabine) are resistant to ADA due to protonation at N-7 instead of N-6^[4] which prevents hydroxylation and deamination at N-6. Cladribine 5'-triphosphate, with similar toxic effects to those of dATP, accumulates in dCK-rich tissues; treatment with cladribine can, therefore, mimic ADA-deficiency.

Due to the lack of a solid patent, the development of the drug for clinical use was severely slowed. Thanks to the efforts of Dennis Carson and Ernest Beutler at Scripps Clinic, La Jolla, cladribine was eventually taken through preclinical and early clinical testing.^[5-7] Under the Orphan Drug Act, cladribine was licensed as Leustatin® in 1994 and has emerged as one of the more important drugs in the therapeutic armament against lymphoproliferative disorders.^[8] The use of cladribine in children was investigated independently at St Jude Children's Hospital, Memphis, USA.^[9] While the metabolism and mechanism of action of cladribine was elucidated early, the clinical pharmacokinetics have not been delineated until recently. The pharmacokinetic data has, however, grown steadily during recent years.

Cladribine is the drug of choice for the treatment of hairy cell leukaemia.^[10,11] It has definite activity

in chronic lymphocytic leukaemia^[12-15] and low-grade non-Hodgkin's lymphoma^[15-18] although the exact role of cladribine in the treatment of these diseases is still a matter of some controversy. The use of purine analogues in the treatment of low-grade lymphoproliferative disorders was recently reviewed.^[19] Responses are also seen in acute myelogenous leukaemia in children^[20] and in psoriatic arthritis.^[21] A randomised, double-blind, cross-over trial showed impressive activity in patients with chronic progressive multiple sclerosis.^[22,23] In experimental systems, cladribine potentiates the immunosuppressive effect of cyclosporin and has potential in the treatment of transplant rejection.^[24]

1. Bioanalysis

The plasma pharmacokinetics of cladribine have been studied during continuous infusion and after intravenous short infusion, subcutaneous injection, oral, and rectal administration. The concentration of cladribine has been determined with liquid chromatography^[25,26] and radioimmunoassay.^[20,27] Liquid chromatography has the advantage of identifying the catabolite 2-chloroadenine (CAde) while radioimmunoassay can be somewhat more




Fig. 1. The chemical structure of cladribine (2-chloro-2'-deoxyadenosine).




Fig. 2. The plasma concentration of cladribine after intravenous [area under the concentration-time curve (AUC) = 791 nmol/L • h], oral (AUC = 878 nmol/L • h), and subcutaneous (AUC = 709 nmol/L • h) administration of cladribine (from Liliemark et al.^[30] with permission).

sensitive (detection limit 1 vs 0.2 nmol/L). The comparison of pharmacokinetic data for cladribine between investigators is obscured by differences in the absorption coefficient ($\epsilon = 15.0 \times 10^3$ L/mol)^[1,28] used for determination of the cladribine concentration in standards.^[5] In the early clinical and pharmacokinetic studies (before 1993) the absorption coefficient for chloroadenine ($\epsilon = 12.6 \times 10^3$ L/mol) was used. Therefore, the dose and plasma concentration in these studies were overestimated by 15%.

2. Bioavailability

2.1 Oral Administration

There are 4 reports on the oral bioavailability of cladribine.^[29-32] The oral bioavailability in these trials varies from 37 to 51% when the saline solution for intravenous administration is given to patients to drink.^[29,30,32] Thus, when administered orally at about twice the intravenous dose, the areas under the concentration-time curve (AUC) are similar (fig. 2).

When compared with 2-hour intravenous infusion (0.12 mg/kg $\approx$ 5 mg/m²) the maximum concentration was slightly higher but the peak briefer after oral (0.24 mg/kg $\approx$ 10 mg/m²) or subcutaneous administration (0.12 mg/kg) [142 nmol/L after intravenous infusion vs 165 nmol/L after oral and 268 nmol/L after subcutaneous administra-

tion].^[30] In some other antimetabolites (i.e. cytarabine and 6-mercaptopurine),^[33,34] bioactivation is impaired when the drug concentrations achieved are above the Michaelis-Menten constant (K_m) of the bioactivating enzymes. The plasma concentration of cladribine achieved by subcutaneous or oral administration is, however, at least one log lower than the K_m of dCK, the intracellular CdA phosphorylation enzyme.^[35] Thus, the drug concentrations achieved with a standard dose are far from saturating the bioactivation.

The interindividual variability of the bioavailability is considerable [coefficient of variation (CV) = 28%] but the variability of the AUC after oral administration is not any greater than that after intravenous administration (CV = 38 vs 36%).^[30]

Cladribine is not stable at low pH (pH < 2). However, attempts to increase the pH in the stomach with omeprazole before the oral administration of cladribine have not improved the bioavailability significantly.^[29] Neither was the use of enteric coated capsules of any benefit.^[30] Concomitant food intake slowed and lowered the uptake of cladribine.^[29] However, despite a limited bioavailability, oral administration of cladribine has been used successfully in the treatment of previously untreated chronic lymphocytic leukaemia^[36,37] and psoriatic arthritis.^[21]

2.2 Subcutaneous Administration

Cladribine has no local tissue toxicity and when given subcutaneously, the bioavailability is 100%.^[30] Subcutaneously administered cladribine was used in 1 large trial on hairy cell leukaemia. The therapeutic results seems to be equivalent with those after continuous intravenous infusion.^[10]

2.3 Rectal Administration

Based on the impressive improvement of the bioavailability of 6-mercaptopurine with rectal administration as compared with oral administration,^[38] an attempt has been made to improve the bioavailability of cladribine with rectal administration. However, cladribine is degraded by bacterial enzymes and the bioavailability by the rectal route is poor, only 20%.^[39]

3. Distribution

During continuous infusion (5 to 10 mg/m² per 24 hours which corresponds to a dose of 0.12 to 0.24 mg/kg per 24 hours)^[40] the concentration of




Fig. 3. The mean plasma concentration of cladribine after 2 hours intravenous infusion in 12 patients. The data are fitted to a 3-compartment open model. The horizontal line shows the steady-state concentration of cladribine in the same patients after continuous intravenous infusion of the same dose during 24 hours. The broken lines represent 1 SD in the population (from Liliemark and Juliusson,^[41] with permission).

cladribine in plasma is 10 to 50 nmol/L,^[6,20,41] while during a 2-hour infusion of 5 mg/m² it is 100 to 400 nmol/L^[27,41,42] (fig. 3). There appears to be a linear dose/concentration relationship for cladribine in this dose range (0.2 mg/m² per hour to 2.5 mg/m² per hour) although Marks et al.^[42] reported a dose-dependent clearance decreasing from 52.7 to 26.5 L/h/m² with increasing dosages from 3.5 to 10.5 mg/m².

The plasma elimination follows a 2- or 3-compartment open model depending on sampling procedure. The terminal half-life ($t_{1/2}$) is relatively long, 7 to 19 hours. The pharmacokinetics of cladribine after intravenous administration are summarised in table I.

3.1 Penetration of the Blood-Brain Barrier

The concentration of cladribine in the cerebrospinal fluid is approximately 25% of the plasma concentration at dose rates between 0.17 mg/m²/h and 2.5 mg/m²/h intravenously in patients without known meningeal disease.^[43,44,46] The kinetics of the cerebrospinal fluid concentration roughly follows those of the plasma.^[43] The cerebrospinal fluid concentration increases linearly with dose.^[43,46] No data are available on the penetration of cladribine into cerebral tissues. However, several responses have been noted in patients with astrocytomas, indicating that the drug is distributed to the brain, at least when the blood-brain barrier is damaged. Furthermore, cerebral toxicity was noted in patients treated with higher doses of cladribine (0.4 to 0.5 mg/kg daily for 7 to 14 days) than commonly used.^[27]

In 2 papers it has been reported that cladribine can indeed have an effect on meningeal disease when administered intravenously.^[47,48] In 1 patient, with a meningeal involvement of Waldenström's macroglobulinaemia, the cerebrospinal fluid concentration of cladribine exceeded that in plasma, which suggests that meningeal involvement increases the penetration of cladribine into the cerebrospinal fluid.^[47]

Table I. Plasma pharmacokinetics of cladribine

Diagnosis	n	Dose/day (mg/m ²)	Duration (h)	Mean AUC (μmol/L • h)	t _{1/2α} mean (min)	t _{1/2β} (h)	t _{1/2γ} (h)	Vd _{ss} mean (SD) [L/m ²]	Cl mean (SD) [L/h/m ²]	Reference
CLL, HCL, and NHL	12	5.5	2	0.59	8	1.1	6.3	368 (216) ^a		41
CLL and NHL	13	5.0	2	0.76		0.7	9.9	53.6 (23.7)	25.9 (7.8)	43
CLL	4	5.0	2	0.70			13.4		39.1 (6.8)	29
Paediatric AML and ALL	5	8.9	24		3.1		14.2	305.1	36.1	20
Paediatric AML	25	8.9	24				19.7	356.6 (225.2)	39.4 (12.4)	44
Solid tumour	25	3.5-10.5	2	0.26-1.47			5.7	121	26.5-52.7 ^b	45
CML	11	6-12	2	0.53-1.14	11.9	1.5	6.0	174	45.1	42

a Vd of the peripheral compartment.

b Dose dependent.

Abbreviations and symbols: ALL = acute lymphocytic leukaemia; AML = acute myelogenous leukaemia; AUC = area under the concentration-time curve; Cl = clearance; CLL = chronic lymphocytic leukaemia; CML = chronic myelogenous leukaemia; h = hour(s); HCL = hairy cell leukaemia; NHL = non-Hodgkin's lymphoma; n = number of patients; t_{1/2α} = distribution half-life; t_{1/2β} = elimination half-life; t_{1/2γ} = terminal half-life; Vd = volume of distribution.

4. Metabolism

4.1 Catabolism

CAdé is the major metabolite in plasma.^[25] The higher concentration of this catabolite in plasma after the oral administration of cladribine (fig. 4) is probably due to the degradation of cladribine by gastric acid and the subsequent absorption of the metabolite or by hepatic or intestinal first-pass effect. CAdé has no cytotoxic or antitumour effect at the concentrations achieved.

4.2 Bioactivation

Cladribine is phosphorylated to its 5'-monophosphate by dCK^[7] and deoxyguanosine kinase.^[49] This latter enzyme is found in mitochondria and a high activity is present in samples from brain tumours and melanomas^[49] and may be of importance for the therapeutic effect in these tumours.^[46] However, deoxyguanosine kinase is a mitochondrial enzyme and it is unclear whether the phosphorylation of cladribine in mitochondria induces the same cytotoxic effects as phosphorylation in the cytoplasm by dCK. dCK phosphorylates a number of nucleoside analogues and is the rate limiting enzyme in the bioactivation of cytarabine (ara-C) and fludarabine, another adenosine deaminase resistant purine analogue (fig. 5). Cladribine,

however, seems to be phosphorylated readily to the monophosphate but, at least *in vitro*, the concentrations of the di- and triphosphate nucleotides are approximately 7 and 3 times lower than those of the monophosphate.^[9,50]

Cytoplasmatic 5'-nucleotidase^[51] dephosphorylates and deactivates cladribine 5'-monophosphate. The level of this enzyme in tumour cells seems to be important for sensitivity to cladribine treatment^[51,52] and probably determines the retention of cladribine nucleotides in tumour cells.

4.3 Intracellular Pharmacokinetics

The intracellular pharmacokinetics of the total cladribine nucleotide pool have been described in hairy cell, chronic lymphocytic, and acute myelogenous leukaemias after intravenous, oral, and subcutaneous administration.^[31] The intracellular concentration of the cladribine nucleotides is several hundred-fold higher than the plasma concentration of the parent drug (fig. 6). Furthermore, the cladribine nucleotides are well retained in leukaemia cells in patients with chronic lymphocytic leukaemia with a terminal t_{1/2} of around 30 hours when the cellular concentration is monitored during 3 to 7 days (fig. 6). These data support the use of intermittent administration, which has been gaining widespread use lately.^[53-55]

However, the retention of cladribine-nucleotides *in vivo* in leukaemia cells of patients with acute myelogenous leukaemia appears to be somewhat lower. During the first 24 hours after administration the $t_{1/2}$ is 9.0 hours in acute myelogenous leukaemia patients as compared to 12.9 hours in chronic lymphocytic and 15.1 hours in hairy cell leukaemia.^[31] Twice-daily administration of cladribine in acute myelogenous leukaemia might, therefore, be worthwhile.

Recently a new method was developed allowing a specific determination of cladribine mono- and triphosphate in leukaemia cells *in vivo*. Preliminary data shows that the pharmacokinetics of the mono- and triphosphate are similar. However, the relation between the 2 intracellular nucleotides seems to vary^[56] (fig. 7).

4.4 Plasma/Cell Concentration Relationship

The interindividual differences in the intracellular metabolism of cladribine are important since

there seems to be no direct relationship between plasma AUC and intracellular cladribine-nucleotide AUC. Thus, the concentration of the active metabolites at the target site, i.e. the malignant cell, cannot be predicted from plasma concentrations in the individual patient. In contrast, the intracellular concentration of cladribine-nucleotides appears to depend on both the plasma cladribine concentration and the activity of dCK in the leukaemia cells (fig. 8).^[57]

5. Pharmacodynamic Relationships

It was recognised early in the development of the drug that the action of cladribine is highly schedule dependent.^[50,58] Therefore continuous infusion for 7 days was chosen as the preferred mode of administration in the early clinical trials.^[5] However, several investigators have shown that intermittent administration of cladribine works as well in both hairy cell leukaemia^[10] and chronic lymphocytic leukaemia.^[13,14]




Fig. 4. The plasma concentration of cladribine and its catabolite, 2-chloroadenine in 1 patient after an intravenous 2-hour infusion (5 mg/m²) and an oral dose (10 mg/m²) of cladribine (Albertoni et al., unpublished data).




Fig. 5. The intracellular metabolism of nucleoside analogues. Deoxycytidine kinase phosphorylates the nucleoside analogues to their 5'-monophosphates and adenosine deaminase deaminates deoxyadenosine. When pentostatin inhibits adenosine deaminase an excess of dATP is formed. Cladribine and fludarabine are resistant to adenosine deaminase. Cladribine is also a substrate for the mitochondrial enzyme deoxyguanosine kinase.

In vitro data suggest that there is no simple relationship between the formation of cladribine triphosphate intracellularly and antileukaemia effect.^[59] Nor was there any correlation between the AUC of the total cladribine nucleotide pool or plasma cladribine concentration and response to treatment in chronic lymphocytic leukaemia.^[57]

On the other hand, a weak ($p = 0.028$) relationship was found between the plasma cladribine AUC and the response in hairy cell leukaemia.^[10] However, considering the lack of correlation between plasma and cellular drug concentrations mentioned above, this finding needs to be assessed critically and needs to be confirmed before its clinical relevance can be determined.

A weak but significant relationship between the activity of dCK in leukaemia cells and response was also found by 2 independent groups.^[52,60]

Thus, the available data indicates that there are indeed unknown factors beyond the bioactivation of cladribine which determine the final response. They do not allow any conclusion on the usefulness of the clinical pharmacokinetics for individualisation of the treatment. However, the intracellular pharmacokinetics of cladribine provides important information on the effect of route and mode of administration for distribution, bioactivation, and retention of the drug at the site of action, the tumour cell. Thus, intracellular pharmacokinetics are an important tool in decision making on the

route and interval of administration in treatment protocols.

6. Excretion

About 21 to 32% of intravenously administered cladribine is excreted unchanged in the urine within the first 24 hours^[42,45,61] while renal clearance is 51% (11 to 85) of the total systemic cladribine clearance.^[44] After oral administration, $25 \pm 21\%$ of the dose (corrected for bioavailability) was excreted unchanged in the urine and $3.8 \pm 1.9\%$ as CAde. A small amount of CAde is found in plasma also after intravenous administration and $1.5 \pm 1.6\%$ of the dose is excreted renally as CAde during the first 24 hours (Lindemalm et al., personal correspondence). Since most trial protocols re-

quire that patients have normal hepatic and renal function, there are little pharmacokinetic or toxicity data on the significance of impaired organ function. It is therefore not possible to give any recommendations on dosage modifications in such situations.

7. Interaction

The only interaction with cladribine which has been well described is with cytarabine. Pretreatment of patients with cladribine increases the intracellular accumulation of cytosine arabinoside 5'-triphosphate (ara-CTP), the active metabolite of cytarabine, by 36 to 40%.^[62,63] This effect might be due to the inhibition of ribonucleotide reductase decreasing deoxyribonucleotide pools, in particu-




Fig. 6. The concentration of cladribine in plasma (bottom of panel) and the concentration of cladribine nucleotides in leukaemic cells (top of panel) in 1 patient with chronic lymphocytic leukaemia given 0.6 mg/kg ($\approx 5 \text{ mg/m}^2$) as a 2-hour intravenous infusions and 4 weeks later as a continuous infusion of the same dose during 5 days. The intracellular concentration of cladribine nucleotides was determined by measuring cladribine after dephosphorylation of the nucleotides by alkaline phosphatase in methanol extracts of leukaemic cells (from Liliemark and Juliusson,^[31] with permission).




Fig. 7. The concentration of cladribine in plasma and the cladribine nucleotides cladribine 5'-monophosphate, and cladribine 5'-triphosphate in leukaemic cells in 2 patients after an oral dose of 10 mg/m² (Albertioni et al.,^[56] with permission).

lar deoxycytidine 5'-triphosphate (dCTP) which is an inhibitor of cytarabine (and cladribine) phosphorylation by dCK. Although there are no data, it can be suspected that other nucleoside analogues which are bioactivated by dCK, e.g. fludarabine and gemcitabine, can be the subject of a similar interaction with cladribine.

8. Interspecies Differences

Pharmacokinetically guided dose escalation has been applied successfully to minimising the number of patients needed for phase I dose finding

studies. Traditionally the dose in phase I trials is based on the LD₁₀ in mice, 10% of the LD₁₀ in mice is used as a starting dose in patients. The dose is then escalated arbitrarily according to a Fibonacci scheme^[64] until the maximum tolerable dose is reached.

The pharmacokinetically guided dose escalation concept is based on the assumption that there is a stronger relationship between the drug concentration (AUC) and toxic effects in mice and humans than there is between dose and toxic effects.^[65] The AUC at LD₁₀ is established in mice. Then the AUC in humans at the starting dose (10% of the LD₁₀) is determined. The subsequent dose escalation is then based on the difference between the murine LD₁₀ and human AUC.

Theoretically this concept is useful for a number of different anticancer drugs. However, for antimetabolites, e.g. fludarabine, the concept would have been less useful as the AUC in humans at the maximum tolerable dose is 10 times lower than that of mice at LD₁₀.^[65] Thus, mice appear to be less sensitive to the toxic effects of fludarabine. This is also the case for cladribine. The K_m of the main bioactivating enzyme, dCK, is 10 times lower for cladribine in human thymocytes as compared with thymocytes in mice, while the V_{max} is similar. Human dCK therefore phosphorylates cladribine more efficiently than does the murine enzyme.^[66]

In the original phase I trial of cladribine, the first 2 patients were given 1 mg/kg/day as a continuous infusion for 7 days based on toxicity in mice.^[6] However, the AUC of cladribine at LD₁₀ in mice is about 50 times larger than that in patients at maximum tolerable dose.^[66] The therapeutic effect was impressive but the patients developed bone marrow failure and died. In subsequent patients the dosage was decreased to one tenth of the starting dose, 0.1 mg/kg/day for 7 days.^[6] This dose was also considered to be the maximum tolerable dose which has been confirmed in more recent phase I trials.^[42] Information on only the plasma pharmacokinetics in mice and humans is therefore not useful for the determination of a safe dosage of

antimetabolites in humans. This shows that knowledge about bioactivation is important when pharmacokinetically guided dose escalation is employed in phase I trials with antimetabolites.

There is also a good correlation between toxic effects *in vivo* in humans and the cytotoxic effect of antimetabolites *in vitro*. Thus, information on the cytotoxic effect on human cells *in vitro* is also useful when decisions are made about the rate of dosage escalation in phase I trials.^[67]




Fig. 8. (Top) The relationship between the area under the concentration-time curve (AUC) of plasma cladribine and intracellular cladribine nucleotides in 69 patients with chronic lymphocytic leukaemia, hairy cell leukaemia and acute myeloid leukaemia treated with cladribine 0.085 to 0.22 mg/kg intravenously or subcutaneously or 0.24 mg/kg orally. **(Bottom)** The relationship between intracellular cladribine nucleotides and the AUCs of plasma cladribine multiplied by the activity of the phosphorylating enzyme deoxycytidine kinase in leukaemic cells in 37 patients with chronic lymphocytic leukaemia, hairy cell leukaemia and acute myeloid leukaemia treated with cladribine 0.085 to 0.22 mg/kg intravenously or subcutaneously or 0.24 mg/kg orally.

9. Conclusion

Pharmacokinetic data on cladribine are slowly accumulating, and now allow more definite recommendations for its administration. Taken together with the available clinical data, there is no support for the use of continuous intravenous infusion of cladribine; subcutaneous injection can supersede intermittent intravenous administration. Finally, due to its variable bioavailability, oral administration is recommended when repeated courses are given (i.e. for most indications except hairy cell leukaemia).

References

- Christensen LF, Broom AD, Robins MJ, et al. Synthesis and biochemical activity selected 2,6-disubstituted-(2-deoxy- α - and β -D-erythro-pentofuranosyl)purines. *J Med Chem* 1972; 15: 735-9
- Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severe impaired cellular immunity. *Lancet* 1972; II (786): 1067-8
- Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes. *J Clin Invest* 1985; 75: 377-83
- Kazimierczuk Z, Vilpo J, Seela F. Base-modified nucleosides related to 2-chloro-2'-deoxyadenosine. *Helv Chim Acta* 1992; 75: 2289-97
- Beutler E. Cladribine. *Lancet* 1992; 340: 952-6
- Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. *Proc Natl Acad Sci USA* 1984; 2232-6
- Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs towards malignant human lymphoblasts in vitro and towards murine L1210 leukemia in vivo. *Proc Natl Acad Sci USA* 1980; 77: 6865-9
- Bryson H, Sorkin E. Cladribine: a review of its pharmacodynamics, pharmacokinetics and therapeutic potential in the treatment of haematological malignancies. *Drugs* 1993; 46: 872-94
- Santana V, Mirro J, Cherrie H, et al. Phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. *J Clin Oncol* 1991; 9: 416-22
- Juliussen G, Haldal D, Hippe E, et al. Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. *J Clin Oncol* 1995; 13: 989-95
- Piro LD, Elison DJ, Saven A. The Scripps clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. *Leuk Lymphoma* 1994; 14 Suppl. 1: 121-5
- Juliussen G, Christiansen I, Mørk-Hansen M, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. *J Clin Oncol* 1996; 14: 2160-6
- Juliussen G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. *Ann Oncol* 1996; 7: 373-9
- Saven A, Carrera CJ, Carson D, et al. Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. *Leuk Lymph* 1991; 5 Suppl.: 133-8

15. Saven A, Emanuele S, Kasty M, et al. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. *Blood* 1995; 86: 1710-6
16. Kay A, Saven A, Carrera C, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. *J Clin Oncol* 1992; 10: 371-7
17. Liliemark J, Hagberg H, Cavallin-Ståhl E, et al. Cladribine (2-CdA) for early low grade non-Hodgkin's lymphoma (LG-NHL) [abstract]. *Blood* 1994; 84 Suppl.: 168
18. Liliemark J, Porwit A, Juliusson G. Intermittent infusion of cladribine in previously treated patients with low-grade non-Hodgkin's lymphoma. *Leuk Lymphoma*. In press
19. Fidas P, Chabner BA, Grossbard ML. Purine analogs for the treatment of low-grade lymphoproliferative disorders. *The Oncologist* 1996; 1: 125-39
20. Santana V, Mirro J, Kearns C, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remissions in relapsed acute myeloid leukemia. *J Clin Oncol* 1992; 10: 364-70
21. Eibschutz B, Baird SM, Weisman MH, et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis: a preliminary report. *Arthritis Rheum* 1995 Nov; 38: 1604-9
22. Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. *Proc Natl Acad Sci USA* 1996; 93: 1716-20
23. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. *Lancet* 1994; 334: 9-13
24. Oberhuber G, Schmid T, Thaler W, et al. 2-Chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation. *Transplantation* 1994; 58: 743-5
25. Albertioni F, Hassan M, Liliemark J. Kinetics of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in isolated perfused rat liver. *Eur J Drug Metab Pharmacokinet* 1995; 30: 225-32
26. Liliemark J, Pettersson B, Juliusson G. Determination of 2-chloro-2'-deoxyadenosine in human plasma. *Biomed Chromatogr* 1991; 5: 262-4
27. Beutler E, Piro LD, Saven A, et al. 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleoside. *Leuk Lymphoma* 1991; 5: 1-8
28. Drug master file for 2-chloro-2'-deoxyadenosine. Warsaw: Foundation for the Development of Diagnostics and Therapy Warsaw, 1992
29. Albertioni F, Juliusson G, Liliemark J. On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA): the influence of food and omeprazole. *Eur J Clin Pharmacol* 1993; 44: 579-82
30. Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans; alternative routes of administration. *J Clin Oncol* 1992; 10: 1514-8
31. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. *Clin Cancer Res* 1995; 1: 385-90
32. Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. *J Clin Oncol* 1996; 14: 978-83
33. Liliemark J, Pettersson B, Engberg B, et al. On the paradoxically concentration dependent metabolism of 6-mercaptopurine by leukemic cells. *Cancer Res* 1990; 50: 108-12
34. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. *Cancer Res* 1987; 47: 3005-11
35. Eriksson S, Kierdaszuk B, Munch-Petersen B, et al. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase towards antiviral and cytostatic nucleoside analogs. *Biochem Biophys Res Commun* 1991; 176: 586-92
36. Juliusson G, Johnson SAN, Christiansen J, et al. Oral 2-chlorodeoxyadenosine (CdA) as primary treatment for symptomatic chronic lymphocytic leukemia (CLL) [abstract]. *Blood* 1993; 10 Suppl. 1: 141
37. Karlsson K, Strömberg M, Johnson SAN, et al. Three-day three-weekly oral cladribine (2-CdA) for chronic lymphocytic leukemia. A preliminary report from a European phase II multicenter study. *Ann Oncol* 1996; 7 Suppl. 3: 68
38. Kato Y, Matsushita T, Uchida H, et al. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukemia: avoidance of 'first pass' metabolism. *Eur J Clin Pharmacol* 1992; 42: 619-22
39. Liliemark J, Albertioni F, Edlund C, et al. Bioavailability and bacterial degradation of rectally administered 2-chloro-2'-deoxyadenosine. *J Pharm Biomed Anal* 1995; 13: 661-5
40. Freireich E, Gehan E, Rall D, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. *Cancer Chemother Rep* 1966; 50: 219-44
41. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. *Cancer Res* 1991; 51: 5570-2
42. Marks RS, Richardson RL, Reid JM, et al. A Phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors [abstract]. *Proc Am Soc Clin Oncol* 1994; 13: 416
43. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine (CdA) in cerebrospinal fluid (CSF) [abstract]. *Blood* 1992; 80 Suppl. 1: 471
44. Kearns CM, Blakley RL, Santana VM, et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. *Cancer Res* 1994; 54: 1235-9
45. Marks RS, Richardson RL, Reid JM, et al. A phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors [abstract]. *Proc Am Soc Clin Oncol* 1994; 13: 416
46. Saven A, Kawasaki H, Carrera CJ, et al. 2-Chlorodeoxyadenosine dose escalation in nonhematological malignancies. *J Clin Oncol* 1993; 11: 671-8
47. Richards AI. Response to meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine. *J Clin Oncol* 1995; 13: 2476
48. Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. *Blood* 1994; 84: 1237-42
49. Wang L, Karlsson A, Arnér ES, et al. Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. *J Biol Chem* 1993; 268: 22847-52
50. Carson DA, Wasson DB, Teatle R, et al. Specific toxicity of 2-chlorodeoxyadenosine towards resting and proliferating human lymphocytes. *Blood* 1983; 62: 737-43
51. Carson DA, Kaye J, Wasson DB. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. *J Immunol* 1981; 126: 348-52

52. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. *Blood* 1993; 81: 597-601
53. Maerevoet M, Delannoy A, Ferrant A, et al. 2-Chlorodeoxyadenosine (CDA) therapy in chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (WD): an update on 77 patients [abstract]. *Blood* 1995; 86 Suppl. 1: 838
54. Mulligan SP, Eliadis P, Dale B, et al. 2-Chlorodeoxyadenosine (2-CDA) in previously untreated chronic lymphocytic leukemia (CLL) – preliminary analysis from the Australian leukemia study group trial [abstract]. *Blood* 1995; 86 Suppl. 1: 349
55. von Rohr A, Bacchi M, Fey MF, et al. 2-Chlorodeoxyadenosine (CDA) by subcutaneous bolus injection: A phase II study in hairy cell leukemia (HCL) [abstract]. *Blood* 1995; 86 Suppl. 1: 350
56. Albertioni F, Lindemalm S, Reichelová V, et al. Intracellular pharmacokinetics of cladribine 5'-mono- (CdAMP) and triphosphate (CdATP) following oral cladribine (CdA) in patients with chronic lymphocytic leukemia. *Proc Am Soc Clin Oncol* 1996; 15: 178
57. Liliemark J, Arnér E, Juliusson G. On the relationship between cladribine (CdA) plasma concentrations, intracellular CdA-nucleotide (CdAN) concentration, deoxycytidine kinase (dCK) and anti-leukemic response in patients with chronic lymphocytic leukemia. *Proc Am Soc Clin Oncol* 1994; 12: 308
58. Petzer AL, Bilgeri R, Zilian U, et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. *Blood* 1991; 78: 2583-7
59. Avery TL, Regh JE, Lumm WC, et al. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effect of 2-bromodeoxyadenosine in drug combinations in mice. *Cancer Res* 1989; 49: 4972-8
60. Arnér E, Spasokoutskaia T, Juliusson G, et al. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukemic patients. *Br J Haematol* 1994; 87: 715-8
61. Albertioni F, Pettersson B, Reichelová V, et al. Analysis of 2-chloro-2'-deoxyadenosine in human blood samples and urine by high-performance liquid chromatography using solid-phase extraction. *Ther Drug Monit* 1995; 16: 413-8
62. Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinocytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. *Blood* 1996; 87: 256-64
63. Juliusson G, Liliemark J. 2-Chlorodeoxyadenosine (CdA) with and without cytosine arabinoside (ara-C) and idarubicin for acute myeloid and lymphoid leukemia: clinical and pharmacokinetic studies. *Br J Haematol* 1994; 87 Suppl. 1: 12
64. Goldsmith MA, Slavik M, Carter SK. Quantitative prediction of drug toxicity in small and large animals. *Cancer Res* 1975; 35: 1354-64
65. Collins J, Grieshaber C, Chabner B. Pharmacologically guided phase I clinical trials based upon preclinical drug development. *J Natl Cancer Inst* 1990; 82: 1321
66. Reichelová V, Juliusson G, Spasokoutskaia T, et al. Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacokinetically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine. *Cancer Chemother Pharmacol* 1995; 36: 524-9
67. Fridborg H, Nygren P, Larsson R. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. *Anticancer Drugs* 1995; 6: 64-9

Correspondence and reprints: Dr Jan Liliemark, Experimental Haematology, Karolinska Institute and Department of Oncology, Karolinska Hospital, S-171 76 Stockholm, Sweden.